These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9935194)

  • 41. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.
    Ottaviani S; Colau D; van der Bruggen P; van der Bruggen P
    Cancer Immunol Immunother; 2006 Jul; 55(7):867-72. PubMed ID: 16151806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
    Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
    Harada M; Ishihara Y; Itoh K; Yamanaka R
    Oncol Rep; 2007 Mar; 17(3):629-36. PubMed ID: 17273744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
    Kobayashi J; Torigoe T; Hirohashi Y; Idenoue S; Miyazaki A; Yamaguchi A; Hiratsuka H; Sato N
    J Transl Med; 2009 Jan; 7():1. PubMed ID: 19123955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection.
    Kurokohchi K; Arima K; Nishioka M
    J Hepatol; 2001 Jun; 34(6):930-5. PubMed ID: 11451179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
    Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
    Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
    Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
    Ohminami H; Yasukawa M; Fujita S
    Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.
    Masuoka M; Yoshimuta T; Hamada M; Okamoto M; Fumimori T; Honda J; Oizumi K; Itoh K
    Viral Immunol; 2001; 14(4):369-77. PubMed ID: 11792066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
    Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
    Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
    J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product.
    Visseren MJ; van der Burg SH; van der Voort EI; Brandt RM; Schrier PI; van der Bruggen P; Boon T; Melief CJ; Kast WM
    Int J Cancer; 1997 Sep; 73(1):125-30. PubMed ID: 9334819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas.
    Tanaka H; Tsunoda T; Nukaya I; Sette A; Matsuda K; Umano Y; Yamaue H; Takesako K; Tanimura H
    Br J Cancer; 2001 Jan; 84(1):94-9. PubMed ID: 11139320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
    Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
    J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
    Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
    Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
    Kobayashi K; Noguchi M; Itoh K; Harada M
    Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung.
    Sugaya M; Takenoyama M; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Ichiki Y; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
    Int J Cancer; 2007 Mar; 120(5):1055-62. PubMed ID: 17131342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.